Regardh C G, Heggelund A, Kylberg-Hanssen K, Lundborg P
Cardiovascular Research Laboratories, Mölndal, Sweden.
Biopharm Drug Dispos. 1990 Oct;11(7):607-17. doi: 10.1002/bdd.2510110706.
The pharmacokinetics of pafenolol were evaluated in 12 healthy subjects after administration of three single IV doses (5, 10, and 20 mg) and three oral single doses (25, 50, and 100 mg). The drug was discontinuously absorbed. A first peak was observed 0.5 to 1.5 h after dosing and a second higher maximum concentration was noted 3 to 5 h after the administration in the majority of the experiments. The mean systemic availability increased from 27 +/- 5 per cent for the oral 25 mg dose to 46 +/- 5 per cent for the 100 mg dose, i.e., an increase of about 70 per cent (p less than 0.05). The half-life of distribution varied between 5 and 6 min and the apparent volume of distribution (Vz) was about 1.11 kg-1. The distribution was linear in the IV dose range studied. Total body clearance was about 300 ml min-1. About 50 per cent of the systemically available dose was excreted unchanged via the kidneys. Total body clearance decreased by about 13 per cent (p less than 0.05) by increasing the dose from 5 to 20 mg IV possibly because of reduced renal elimination. Mean terminal t1/2 of the IV dose was approximately 3.5 h. The corresponding t1/2 of the oral dose was approximately 6 h indicating absorption rate-limited kinetics of the oral dose.
在12名健康受试者中,分别给予三种静脉单次剂量(5毫克、10毫克和20毫克)和三种口服单次剂量(25毫克、50毫克和100毫克)后,评估了帕非诺洛尔的药代动力学。该药物吸收不连续。在大多数实验中,给药后0.5至1.5小时观察到第一个峰值,给药后3至5小时出现第二个更高的最大浓度。口服25毫克剂量的平均全身生物利用度从27±5%增加到100毫克剂量的46±5%,即增加了约70%(p<0.05)。分布半衰期在5至6分钟之间,表观分布容积(Vz)约为1.11kg-1。在所研究的静脉剂量范围内,分布呈线性。全身清除率约为300ml/min。约50%的全身可用剂量通过肾脏以原形排泄。将静脉剂量从5毫克增加到20毫克时,全身清除率降低了约13%(p<0.05),这可能是由于肾脏清除减少所致。静脉剂量的平均终末t1/2约为3.5小时。口服剂量的相应t1/2约为6小时,表明口服剂量的吸收速率受限动力学。